Latest Strategy News

Nido Education Limited has completed the acquisition of two child care services for $6 million, projecting a $1.3 million EBIT boost in 2026. Both services boast occupancy rates above 90%, reinforcing Nido’s incubation growth strategy.

Moho Resources has sold its Silver Swan North Project to Mineral Mining Services, boosting funds for its maiden drilling program at the promising Bush Chook Project in Western Australia’s Pilbara region.

APA Group’s BBB credit rating is affirmed by S&P with a key modification that expands its borrowing power by over $1 billion, positioning the energy infrastructure giant for accelerated growth.

Accelerate Resources has raised A$900,000 through a share placement to fund expanded drilling and geophysical surveys at its Balagundi Gold Project in Western Australia.

Eden Innovations has landed its largest order yet from Holcim Ecuador, signalling accelerating demand for its EdenCrete®Pz7 concrete additive and reinforcing its growth trajectory.

Artrya Limited has landed a significant three-year commercial agreement with Northeast Georgia Health System, marking its second U.S. customer for the AI-powered Salix platform. This deal accelerates Artrya’s footprint in cardiovascular diagnostics across a major U.S. health network.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

Cobalt Blue Holdings has raised $5.3 million through a discounted placement to advance its Kwinana Cobalt Refinery and Broken Hill projects, reinforcing its position in the critical minerals sector.

Horizon Minerals has formalised a key Land Use Agreement with the Marlinyu Ghoorlie Native Title Claimant Group, setting a cooperative framework for heritage protection and project development across its extensive eastern goldfields tenure.

American Rare Earths has appointed mining veteran Mark Wall as CEO to lead its transition from exploration to production, focusing on advancing its flagship Halleck Creek project and expanding its U.S. market presence.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

Venus Metals Corporation has issued a firm recommendation to reject QGold Pty Ltd’s unsolicited $0.17 per share takeover offer, arguing it undervalues key assets and offers no premium. The board highlights significant upside potential in its portfolio and warns shareholders against accepting an opportunistic bid.